دورية أكاديمية
أعرض في EDS

Challenges and Strategies in Implementing Novel Kidney Protective and Cardioprotective Therapies in Patients With Diabetes and Kidney Disease.

التفاصيل البيبلوغرافية
العنوان: Challenges and Strategies in Implementing Novel Kidney Protective and Cardioprotective Therapies in Patients With Diabetes and Kidney Disease.
المؤلفون: Limonte CP; Division of Nephrology, Department of Medicine, University of Washington, Seattle, WA; Kidney Research Institute, University of Washington, Seattle, WA. Electronic address: climonte@uw.edu., Lamprea-Montealegre JA; Department of Medicine, University of California, San Francisco, CA; Kidney Health Research Collaborative, University of California, San Francisco, CA., Tuttle KR; Division of Nephrology, Department of Medicine, University of Washington, Seattle, WA; Providence Health Care, Spokane, WA.
المصدر: Seminars in nephrology [Semin Nephrol] 2024 Mar; Vol. 44 (2), pp. 151520. Date of Electronic Publication: 2024 May 05.
نوع المنشور: Journal Article; Review
اللغة: English
بيانات الدورية: Publisher: W.B. Saunders Country of Publication: United States NLM ID: 8110298 Publication Model: Print-Electronic Cited Medium: Internet ISSN: 1558-4488 (Electronic) Linking ISSN: 02709295 NLM ISO Abbreviation: Semin Nephrol Subsets: MEDLINE
أسماء مطبوعة: Publication: Philadelphia Pa : W.B. Saunders
Original Publication: [New York, N.Y.] : Grune & Stratton, [c1981-
مواضيع طبية MeSH: Renal Insufficiency, Chronic*/therapy , Sodium-Glucose Transporter 2 Inhibitors*/therapeutic use, Humans ; Mineralocorticoid Receptor Antagonists/therapeutic use ; Cardiovascular Diseases/prevention & control ; Glucagon-Like Peptide-1 Receptor/agonists ; Diabetic Nephropathies/prevention & control ; Diabetic Nephropathies/therapy ; Diabetes Mellitus, Type 2/complications ; Diabetes Mellitus, Type 2/therapy
مستخلص: Chronic kidney disease (CKD) is highly prevalent, estimated to affect over 800 million people worldwide. Diabetes is a leading cause of kidney disease. Both diabetes and CKD are associated with a high risk of cardiovascular disease and related morbidity and mortality. Over the last several years, there has been a shift in focus toward integrating kidney and cardiovascular care, particularly in diabetes. Sodium-glucose cotransporter 2 inhibitors, glucagon-like peptide 1 receptor agonists, and nonsteroidal mineralocorticoid receptor antagonists have rapidly become cornerstones of kidney and cardiovascular risk-focused care in diabetes and CKD. However, present-day use of these agents is low, and disparities in use by race, ethnicity, age, sex, and comorbidities are apparent. Challenges in implementation of kidney protective and cardioprotective therapies include low rates of diabetes and CKD screening, lack of provider comfort and subspecialty reliance, inconsistencies across professional society guidelines, high rates of drug discontinuation, and prohibitive costs. Effective implementation of kidney protective and cardioprotective therapies necessitates a multifaceted approach and active engagement of patients, pharmacists, primary care providers, subspecialty providers, and health care system leaders as key stakeholders. Implementation efforts should be practical and incorporate collaborative, multidisciplinary team-based approaches. Successful implementation of kidney protective and cardioprotective therapies has the potential to improve overall health outcomes and ameliorate health care disparities.
(Copyright © 2024 Elsevier Inc. All rights reserved.)
References: Lancet. 2023 Sep 23;402(10407):1020-1021. (PMID: 37597525)
Circ Cardiovasc Qual Outcomes. 2020 Nov;13(11):e007264. (PMID: 33176463)
J Am Soc Nephrol. 2006 Jun;17(6):1695-702. (PMID: 16641153)
Am J Physiol Renal Physiol. 2016 Dec 1;311(6):F1087-F1108. (PMID: 27707707)
J Clin Transl Sci. 2021 May 14;5(1):e126. (PMID: 34367671)
J Am Coll Cardiol. 2007 Jul 17;50(3):217-24. (PMID: 17631213)
JAMA Netw Open. 2021 Apr 1;4(4):e216139. (PMID: 33856475)
N Engl J Med. 2022 Sep 15;387(11):967-977. (PMID: 36018037)
Nat Rev Nephrol. 2022 Nov;18(11):696-707. (PMID: 36104509)
Diabetes Res Clin Pract. 2022 Jan;183:109118. (PMID: 34883189)
N Engl J Med. 2020 Oct 8;383(15):1436-1446. (PMID: 32970396)
BMC Public Health. 2023 Jun 23;23(1):1218. (PMID: 37353821)
Eur J Heart Fail. 2010 Aug;12(8):861-5. (PMID: 20484366)
Lancet Diabetes Endocrinol. 2022 Jan;10(1):16-17. (PMID: 34919863)
JAMA Netw Open. 2019 Dec 2;2(12):e1918169. (PMID: 31860111)
Diabetes Care. 2014;37(1):24-30. (PMID: 24356594)
Diabetes Obes Metab. 2022 Jul;24(7):1277-1287. (PMID: 35322567)
Am J Kidney Dis. 2020 Aug;76(2):174-183. (PMID: 32305206)
Nephrol Dial Transplant. 2023 Aug 31;38(9):2041-2051. (PMID: 36651820)
Kidney Int Rep. 2021 Nov 09;7(3):424-435. (PMID: 35257055)
Am Heart J. 2020 Jun;224:47-53. (PMID: 32304879)
JAMA Health Forum. 2021 Dec 17;2(12):e214205. (PMID: 35977296)
J Am Soc Nephrol. 2009 Aug;20(8):1813-21. (PMID: 19443635)
JAMA Netw Open. 2021 Feb 1;4(2):e2035792. (PMID: 33523188)
JAMA. 2022 Sep 6;328(9):861-871. (PMID: 36066519)
BMJ Open Diabetes Res Care. 2020 May;8(1):. (PMID: 32448787)
Diabetes Obes Metab. 2023 Oct;25(10):2970-2979. (PMID: 37395334)
Circulation. 2019 Nov 5;140(19):1569-1577. (PMID: 31474116)
Clin Nephrol. 2009 Jun;71(6):643-51. (PMID: 19473633)
Diabetes Care. 2018 Nov;41(11):2306-2315. (PMID: 30131397)
J Am Soc Nephrol. 2016 Sep;27(9):2861-71. (PMID: 26823551)
Eur J Prev Cardiol. 2017 Oct;24(15):1637-1645. (PMID: 28870145)
Lancet Diabetes Endocrinol. 2015 Jul;3(7):514-25. (PMID: 26028594)
J Am Soc Nephrol. 2013 Feb;24(2):302-8. (PMID: 23362314)
JAMA Health Forum. 2021 Dec 17;2(12):e214182. (PMID: 35977298)
N Engl J Med. 2023 Jan 12;388(2):117-127. (PMID: 36331190)
N Engl J Med. 2019 Jun 13;380(24):2295-2306. (PMID: 30990260)
Nat Rev Nephrol. 2022 Jan;18(1):56-70. (PMID: 34675379)
Heart Fail Rev. 2016 Jan;21(1):11-23. (PMID: 26542377)
J Am Coll Cardiol. 2022 May 3;79(17):e263-e421. (PMID: 35379503)
Int J Equity Health. 2019 May 31;18(1):80. (PMID: 31151452)
Nat Rev Nephrol. 2022 May;18(5):294-306. (PMID: 35145275)
Kidney Int. 2022 Nov;102(5S):S1-S127. (PMID: 36272764)
Med Clin North Am. 2013 Jan;97(1):59-74. (PMID: 23290730)
Kidney Int. 2022 Aug;102(2):248-260. (PMID: 35661785)
Hypertension. 2018 Jun;71(6):e13-e115. (PMID: 29133356)
Nephrol Dial Transplant. 2021 Sep 27;36(10):1893-1899. (PMID: 33367872)
Curr Diab Rep. 2020 Mar 12;20(4):12. (PMID: 32166504)
J Clin Pharm Ther. 2020 Dec;45(6):1271-1277. (PMID: 32533743)
Lancet. 2020 Feb 29;395(10225):709-733. (PMID: 32061315)
Nephrol Dial Transplant. 2017 Apr 1;32(suppl_2):ii121-ii128. (PMID: 28201666)
N Engl J Med. 2020 Dec 03;383(23):2219-2229. (PMID: 33264825)
Diabetes Res Clin Pract. 2022 Jan;183:109119. (PMID: 34879977)
Clin J Am Soc Nephrol. 2017 Dec 7;12(12):1984-1990. (PMID: 29054846)
Am J Kidney Dis. 2005 Oct;46(4):587-94. (PMID: 16183412)
Kidney Int. 2019 Nov;96(5):1048-1050. (PMID: 31582227)
Lancet. 2023 Sep 23;402(10407):1052-1064. (PMID: 37597522)
Med Care Res Rev. 2012 Apr;69(2):123-57. (PMID: 22203646)
Diabetes. 2009 Jul;58(7):1651-8. (PMID: 19401416)
J Card Fail. 2007 Aug;13(6):422-30. (PMID: 17675055)
N Engl J Med. 2021 Dec 9;385(24):2252-2263. (PMID: 34449181)
Nephrol Dial Transplant. 2007 Mar;22(3):778-83. (PMID: 17166857)
BMC Health Serv Res. 2020 Mar 12;20(1):190. (PMID: 32164706)
Clin J Am Soc Nephrol. 2021 Oct;16(10):1590-1600. (PMID: 34103350)
Biomedicines. 2023 Mar 13;11(3):. (PMID: 36979855)
Implement Sci. 2011 Apr 23;6:42. (PMID: 21513547)
Circulation. 2023 Nov 14;148(20):1606-1635. (PMID: 37807924)
JAMA Cardiol. 2023 Jul 1;8(7):652-661. (PMID: 37212192)
N Engl J Med. 2022 Sep 22;387(12):1089-1098. (PMID: 36027570)
Nephrol Dial Transplant. 2016 Feb;31(2):206-13. (PMID: 25550448)
J Am Heart Assoc. 2021 Jul 6;10(13):e021084. (PMID: 33998258)
Clin J Am Soc Nephrol. 2011 Oct;6(10):2364-73. (PMID: 21852664)
JAMA Netw Open. 2023 Jul 3;6(7):e2326230. (PMID: 37498594)
Front Public Health. 2020 May 12;8:134. (PMID: 32478025)
Am J Kidney Dis. 2023 Jul;82(1):53-62.e1. (PMID: 36702340)
Diabetes Care. 2021 Sep;44(9):2025-2032. (PMID: 34353883)
Clin J Am Soc Nephrol. 2022 Jul;17(7):1092-1103. (PMID: 35649722)
Can J Kidney Health Dis. 2022 Feb 28;9:20543581221081207. (PMID: 35251673)
Diabetes Care. 2009 Oct;32(10):1833-8. (PMID: 19587367)
Lancet. 2012 Nov 10;380(9854):1662-73. (PMID: 23013602)
Front Pharmacol. 2020 Jun 30;11:967. (PMID: 32694999)
Acta Diabetol. 2023 Mar;60(3):401-411. (PMID: 36576563)
Nephrol Dial Transplant. 2012 Aug;27(8):3182-6. (PMID: 22442392)
Nephrol Dial Transplant. 2023 Feb 28;38(3):630-643. (PMID: 35389468)
Diabetes Care. 2022 Dec 1;45(12):2900-2906. (PMID: 36156061)
Physiol Rev. 2013 Jan;93(1):137-88. (PMID: 23303908)
PLoS One. 2019 Aug 22;14(8):e0221325. (PMID: 31437198)
Diabetologia. 2010 Nov;53(11):2312-9. (PMID: 20665208)
J Diabetes Complications. 2022 Jun;36(6):108204. (PMID: 35537891)
معلومات مُعتمدة: K23 DK135789 United States DK NIDDK NIH HHS
فهرسة مساهمة: Keywords: Chronic kidney disease; GLP-1 RA; SGLT2; diabetes; implementation
المشرفين على المادة: 0 (Sodium-Glucose Transporter 2 Inhibitors)
0 (Mineralocorticoid Receptor Antagonists)
0 (Glucagon-Like Peptide-1 Receptor)
تواريخ الأحداث: Date Created: 20240505 Date Completed: 20240728 Latest Revision: 20240730
رمز التحديث: 20240730
مُعرف محوري في PubMed: PMC11283968
DOI: 10.1016/j.semnephrol.2024.151520
PMID: 38705774
قاعدة البيانات: MEDLINE
الوصف
تدمد:1558-4488
DOI:10.1016/j.semnephrol.2024.151520